Cue biopharma reports fourth quarter and full year 2023 financial results and updated business highlights

Boston, april 08, 2024 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific t cells, today reported fourth quarter and full year 2023 financial results.
CUE Ratings Summary
CUE Quant Ranking